Effects of Combined Deferiprone and Deferoxamine Chelation Therapy on Iron Load Indices in β-Thalassemia

REFERENCES

• Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004; 89(10)1187–1193
   PubMed Web of Science ®Google Scholar
• Aessopos A, Farmakis D, Hatziliami A, Fragodimitri C, Karabatsos F, Joussef J, Mitilineou E, Diamanti-Kandaraki E, Meletis J, Karagiorga M. Cardiac status in well-treated patients with thalassemia major. Eur J Haematol 2004; 73(5)359–366
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, Sabato V, Melevendi C, Cappellini MD, Verlato G. Survival and disease complications in thalassemia major. Ann NY Acad Sci 1998; 850: 227–231
   PubMed Web of Science ®Google Scholar
• Brittenham GM, Badman DG. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Workshop. Noninvasive measurement of iron: report of an NIDDK workshop. Blood 2003; 101(1)15–19
   PubMed Web of Science ®Google Scholar
• Tanner MA, He T, Westwood MA, Firmin DN, Pennell DJ. Thalassemia International Federation Heart T2* Investigators. Multicenter validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica. 2006; 91(10)1388–1391
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, Porter JB, Walker JM, Pennell DJ. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22(23)2171–2179
   PubMed Web of Science ®Google Scholar
• Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 2004; 103(5)1934–1936
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, Porter JB, Walker JM, Pennell DJ. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004; 127(3)348–355
   PubMed Web of Science ®Google Scholar
• Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia. Blood 2000; 95(4)1229–1236
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. New chelation therapies and emerging chelating drugs for the treatment of iron overload. Expert Opin Emerg Drugs 2006; 11(1)1–5
   PubMedGoogle Scholar
• Dancey JT, Deubelbeiss KA, Harker LA, Finch CA. Ferrokinetics in man. Medicine (Baltimore) 1970; 49(1)17–53
   PubMedGoogle Scholar
• Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001; 47–61
   PubMedGoogle Scholar
• Mourad HF, Hoffbrand VA, Sheikh-Taha M, Koussa S, Khoriaty IA, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overload thalassaemia patients. Br J Haematol 2003; 121(1)187–189
   PubMed Web of Science ®Google Scholar
• Kontoghiorges JG, Pattichi K, Hadjigavriel M, Kolnagou A. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Transfus Sci 2000; 23(3)211–223
   PubMedGoogle Scholar
• Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R. Randomized controlled trial of deferiprone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107(9)3738–3744
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Economides Ch, Eracleous E, Kontoghiorghes GJ. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. Hemoglobin 2006; 30(2)219–227
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, Nair SV, Anderson LJ, Walker JM, Pennell DJ. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson 2006; 8(3)543–547
   PubMed Web of Science ®Google Scholar
• Aessopos A, Deftereos S, Tsironi M, Karabatsos F, Yousef J, Fragodimitri C, Hatziliami A, Karagiorga M. Predictive echo-Doppler indices of left ventricular impairment in β-thalassemic patients. Ann Hematol 2007; 86(6)429–434
   PubMedGoogle Scholar
• Galanello R, Kattamis A, Piga A, Fischer R, Leoni G, Ladis V, Voi V, Lund U, Tricta F. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica 2006; 91(9)1241–1243
   PubMed Web of Science ®Google Scholar
• Kattamis A, Ladis V, Berdousi H, Kelekis NL, Alexopoulou E, Papasotiriou I, Drakaki K, Kaloumenou I, Galani A, Kattamis C. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cells Mol Dis 2006; 36(1)21–25
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators. Hemoglobin 2006; 30(2)239–249
   PubMed Web of Science ®Google Scholar